InMode Ltd. (NASDAQ:INMD) Stock Has Consensus Price Target of $16.00

InMode Ltd. (NASDAQ:INMD) has been given an average recommendation of “Hold” by the seven analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $16.00.

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of InMode in a report on Thursday, August 6th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Inspire Investing LLC increased its holdings in InMode by 6.1% during the 1st quarter. Inspire Investing LLC now owns 19,366 shares of the healthcare company’s stock valued at $265,000 after purchasing an additional 1,111 shares in the last quarter. IFP Advisors Inc acquired a new position in InMode in the second quarter worth $31,000. Blue Trust Inc. boosted its stake in InMode by 69.4% in the first quarter. Blue Trust Inc. now owns 5,567 shares of the healthcare company’s stock worth $76,000 after purchasing an additional 2,281 shares in the last quarter. Plan A Wealth LLC grew its holdings in shares of InMode by 20.3% during the second quarter. Plan A Wealth LLC now owns 17,720 shares of the healthcare company’s stock worth $259,000 after purchasing an additional 2,991 shares during the last quarter. Finally, First Trust Advisors LP grew its holdings in shares of InMode by 19.6% during the first quarter. First Trust Advisors LP now owns 24,911 shares of the healthcare company’s stock worth $341,000 after purchasing an additional 4,084 shares during the last quarter. 68.04% of the stock is owned by hedge funds and other institutional investors.

InMode Stock Up 0.1%

Shares of NASDAQ INMD opened at $14.01 on Monday. The stock’s fifty day simple moving average is $14.78 and its 200 day simple moving average is $14.38. The stock has a market capitalization of $805.29 million, a price-to-earnings ratio of 11.39 and a beta of 2.03. InMode has a 52-week low of $12.72 and a 52-week high of $16.74.

InMode (NASDAQ:INMD) last announced its earnings results on Wednesday, August 5th. The healthcare company reported $0.35 EPS for the quarter, meeting the consensus estimate of $0.35. InMode had a return on equity of 11.99% and a net margin of 20.69%.The business had revenue of $95.59 million during the quarter, compared to the consensus estimate of $94.89 million. During the same period in the prior year, the business posted $0.47 earnings per share. InMode’s revenue was up .0% compared to the same quarter last year.

InMode Company Profile

InMode Ltd. is an Israel-based medical technology company that develops, manufactures and markets energy-based platforms for aesthetic and medical treatments. Its technologies are designed to support minimally invasive and noninvasive procedures in areas such as skin rejuvenation, facial and body contouring, hair removal, intimate health and other soft-tissue applications.

The company’s product portfolio includes radiofrequency and other energy-based systems sold under brands such as Morpheus8, BodyTite, FaceTite, Forma and Lumecca.